A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.

开始日期2024-03-01

申办/合作机构

The Cleveland Clinic Foundation

NCT05503082 / Recruiting临床4期IIT

Ubrogepant Efficacy and Safety in the Treatment of Acute Migraine in Patients Currently Treated With CGRP Monoclonal Antibodies (CGRPmAbs)

This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.

开始日期2022-09-06

申办/合作机构

AbbVie, Inc.

NCT05654298 / CompletedN/AIIT

Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin

The involvement of calcitonin gene-related peptide (CGRP) in the cinnamaldehyde-induced dermal blood flow increase and in the mechanism of action of triptans will be investigated. The capsaicin-induced dermal blood flow will be incorporated as a positive control; histamine skin pricks as a negative control. Changes in dermal blood flow will be measured with laser speckle contrast imaging.

开始日期2022-03-15

申办/合作机构

Katholieke Universiteit Leuven

100 项与 Ubrogepant 相关的临床结果

登录后查看更多信息

100 项与 Ubrogepant 相关的转化医学

登录后查看更多信息

100 项与 Ubrogepant 相关的专利（医药）

登录后查看更多信息

128

项与 Ubrogepant 相关的文献（医药）

2024-02-15·Neurology and therapy

Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study.

Article

作者: Taoufik Alsaadi ; Reem Suliman ; Vanessa Santos ; Ibrahim Al Qaisi ; Princess Carmina ; Batool Aldaher ; Shadi Haddad ; Yazan Bader

INTRODUCTION:

The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In clinical practice gepants might be considered as a valid option to treat acute attacks in patients with migraine who are treated with mAbs. However, the safety and tolerability of such a combination is not well addressed in the real-world setting. We designed this study to evaluate the safety and tolerability of combining CGRP mAbs with gepants in the management of migraines.

METHODS:

This was a retrospective, real-world, exploratory study. The participants included within the study were adult (≥ 18 years) patients diagnosed with migraine. Screening for patients who were treated with at least one GCRP mAbs was done. Data was collected from one site, the American Center for Psychiatry and Neurology, Abu Dhabi UAE. A total of 516 patients taking CGRP mAbs were identified. Extracted data from patients' electronic medical records included patient demographics, migraine characteristics, prescribed treatments, and adverse events (AEs). The tolerability and safety of the combination therapy was evaluated on the basis of documented AEs.

RESULTS:

Among the identified 516 patients, 234 were administered gepants in addition to the CRGP mAb (215, rimegepant; 19, ubrogepant). Eleven of the 234 patients switched from rimegepant to urogepant as a result of lack of efficacy; one patient switched from urogepant to zolmitriptan because of the lack of insurance coverage of the former medication. Among all the patients included in this study, three AEs were documented. These AEs were generally mild and transient and hence did not lead to discontinuation of treatment. Moreover, 42 of the 234 (17.9%) patients were switched from one class of CGRP mAbs to another at least once while continuing treatment with the assigned gepants.

CONCLUSION:

The findings of this study demonstrate that combining CGRP mAbs with gepants is a safe and well-tolerated treatment approach for migraine. Future studies are warranted to further validate these findings and explore long-term outcomes.

2024-02-05·The journal of headache and pain

Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials.

Review

作者: Xinxin Deng ; Liying Zhou ; Cui Liang ; Xue Shang ; Xu Hui ; Wendi Liu ; Shanshan Liang ; Yongsheng Wang ; Meng Xu ; Kangle Guo ; Kehu Yang ; Xiuxia Li

OBJECTIVE:

To compare the outcomes associated with the use of lasmiditan, rimegepant, ubrogepant, and zavegepant for the acute management of migraine headaches.

METHODS:

We searched four electronic databases from database inception to August 31, 2023, to identify randomized controlled trials (RCTs) that report efficacy and safety for the acute treatment of migraine. The risk of bias in the included RCTs was evaluated according to the Cochrane tool, and the certainty of evidence using the CINeMA approach. We conducted frequentist network meta-analyses (NMA) to summarise the evidence. Data were analyzed using R-4.3.1.

RESULTS:

A total of 18 eligible studies including 10 different types of interventions with 22,429 migraine patients were included. NMA results showed that compared to ubrogepant (25 mg and 50 mg) and zavegepant, lasmiditan (100 mg and 200 mg) exhibits an elevated probability of achieving pain relief within a 2-hour interval. Similarly, relative to zavegepant, rimegepant (75 mg) and ubrogepant (50 mg and 100 mg) demonstrate an enhanced likelihood of sustaining pain relief over a 24-hour period. Furthermore, in contrast to ubrogepant (25 mg) and lasmiditan (50 mg), rimegepant (75 mg) presents a heightened probability of achieving freedom from photophobia within 2 h. Regarding safety, lasmiditan carries the highest risk of adverse events, which are associated with an increased incidence of adverse effects, including dizziness, somnolence, asthenia, paresthesia, and fatigue.

CONCLUSIONS:

In this NMA, a spectrum of evidence ranging from very low to high levels underscores the favorable efficacy and tolerability of rimegepant 75 mg and ubrogepant 100 mg, positioning them as potential candidates for the acute management of migraine. Concurrently, lasmiditan (100 mg and 200 mg) exhibits notable efficacy, albeit accompanied by an increased susceptibility to adverse events. These findings should still be approached with caution, primarily due to the intrinsic limitations associated with indirect comparisons.

2024-01-23·Clinical pharmacology in drug development

Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults.

Article

作者: Ramesh Boinpally ; Joel Trugman

Ubrogepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. The objectives of this study were to evaluate (1) single-dose pharmacokinetics (PK) and dose proportionality of ubrogepant in Japanese participants, (2) the safety and tolerability of ubrogepant in healthy Japanese and White participants, and (3) to compare the PK of ubrogepant in Japanese versus White participants. A total of 48 participants were enrolled into 4 cohorts (N = 12 [9 active + 3 placebo] per cohort). A single dose was administered on Day 1 following an overnight fast to assess the PK of ubrogepant at 3 dose levels and test dose proportionality between 25 and 100 mg in Japanese participants. White participants were randomly assigned to ubrogepant (100 mg) or placebo. Dose proportionality was observed in the dose range of 25-100 mg in Japanese participants. Systemic exposure was 20% lower in Japanese participants as compared with White participants, but this difference is unlikely to be clinically relevant. Single doses of ubrogepant (25-100 mg) had a safety profile similar to placebo, and no differences in the safety profile of ubrogepant 100 mg were observed between Japanese versus White participants.

项与 Ubrogepant 相关的新闻（医药）

2024-04-08

·GBIHealth

年度收藏：跨国药企核心产品管线布局、研发进度-2023 H2（上篇）

引文跨国药企掌握着全球医药行业最强大的网络资源和决策智慧，他们用真金白银投票选择的方向有更大概率是较符合技术进步规律的（当然这既不意味着他们的决策一定正确、也不意味着这些决策能够被有效执行），通过对他们所有核心产品管线进行系统梳理并定期更新，就有助于我们系统性地了解在大药企自己的话语体系里，究竟哪些方向是在做的、有进展的、值得期待的，从而可以对判断到底什么是所谓“主流技术方向”有更全面直观的依据。本篇将为大家梳理礼来、诺和诺德、强生、默沙东、艾伯维五家企业的管线情况。在GLP-1横扫一切的强势驱动下，无论是业绩和市值，还是各自的产品布局，全球大药企都在经历深刻的变局，甚至可以说进行了颠覆性的重排，仅是下面这张摘要图与半年前相比就有不小的差异。- 左右滑动查看更多 -Lilly礼来礼来在2023年一骑绝尘成功登顶全球药企市值之冠，更夸张的是在2024年刚过两个月又从5,000多亿飚到7,000多亿，眼看就要冲着人类有史以来第一个万亿市值药企的壮举而去了。不过，这疯狂的市值还是有大幅预支未来成长之嫌，毕竟过往业绩虽然表现不俗，但也绝不是成倍的爆发式增长，且看未来是“预支”还是“透支”了。当然，礼来的业绩成长本身确实非常震撼，Tirzepatide在第一个完整销售年度豪取53亿美元、其中Q4单季24亿，在这种震古烁今的爬坡速度驱动下，礼来整体收入额一举从2022年的285亿跃升到2023年的341亿，而且仍处在继续向上跃升的过程中，2024年的业绩指引就是收入提升到410亿左右。- 左右滑动查看更多 -管线的攻城略地仍在发力：在万众瞩目的减肥线上，Tirzepatide肥胖适应症终于获批、并公布了MASH二期临床topline数据，Retatrutide和Orforglipron的多个三期临床先后启动；自免线上，Mirikizumab终于获批、并公布了CD三期临床结果，而Lebrikizumab却收到了FDA的CRL；Donanemab上市却意外地再次被推迟；肿瘤线上，Pirtobrutinib获批CLL/SLL适应症，从POINT收购来的核药PNT-2002也加入管线。- 左右滑动查看更多 -NOVO NORDISK诺和诺德诺和诺德在这波GLP-1狂潮中，市值从1,000亿飙升到接近6,000亿，与礼来呈一时瑜亮之势，在公司创立百年之际达到了可以说是从未有过的高度。看诺和诺德这十年以来的业绩成长，也确实配得上市值的提升。Semaglutide的三个品牌合计在2023年带来了近220亿美元销售额，不过近几个季度在GLP-1中的处方量市场份额已经开始走平，Tirzepatide迅速爬坡带来的竞争压力肉眼可见。- 左右滑动查看更多 -产能制约依然是严重瓶颈，特别是从2023年5月之后低剂量的供应出现明显的受限、以至于对国际市场还会实施供应量限制，从2024年1月开始逐渐增加供应能力，比起半年报时候“will remain restricted”的表述来看应该是有所缓解；产能扩建则继续加码，连续三年持续Capex翻倍的计划。- 左右滑动查看更多 -最重要的研发进展当然还属Semaglutide获批用于心血管风险保护、公布慢性肾病和HFpEF等三期临床结果，以及刚刚公布Amycretin一期的惊艳减重数据；其他值得关注的进展包括高草酸尿症RNAi疗法Nedosiran终于获批，Icosema完成三期临床，从中国药企KBP收购高血压资产等；瘦身也在持续，两个罕见病疗法Belcesiran和Eclipse先后消失在管线中。- 左右滑动查看更多 -J&J强生强生虽然业绩持续稳定，但市值近期下滑到4,000亿以下，被礼来与诺和诺德连续超车。强生医药板块的业绩在大药企中还是相当稳健，其中Ustekinumab和Daratumumab两大引擎的驱动力都非常充足，Guselkumab和Macitentan+Selexipag也表现不俗，但Ibrutinib、Infliximab、Abiraterone、Paliperidone等曾经的超重磅品种确实老态渐显。研发方面最突出的依然是在多发性骨髓瘤领域的“遮断性”优势，不过近期高歌猛进似有放缓，主要进展包括：Talquetamab获得欧盟批准；Teclistamab两周一次剂型获批；Daratumumab皮下剂型公布一线可移植MM患者的三期临床数据；Cilta-cel二线MM适应症获得欧盟积极意见；BCMA/CD3/GPRC5D三抗JNJ-5322公布一期临床数据。其他值得关注的进展包括：2019年从Taris收购来的新型膀胱内药物输送系统TAR-200/201分别公布了二期和一期数据；FcRn单抗Nipocalimab公布二期RA数据并获得FDA突破性认证；FGFR抑制剂Erdafitinib获得FDA完全批准并公布三期临床THOR2研究结果。管线新陈代谢正在进行，从收购Ambrx获得ARX-517/788等ADC资产，而RPGR AAV从管线中被拿掉。- 左右滑动查看更多 -MSD默沙东默沙东近期收入端依然表现稳健，K药仍在增长并稳住了药王地位（虽然刚上位没多久），HPV疫苗也增速不减，这两大定海神针填上了Molnupiravir急速缩水以及Sitagliptin专利悬崖带来的缺口，市值还是逼近3,000亿。研发进展中依然一大半都还是围绕K药的各种扩适应症和联用方案，近期主要进展包括：围手术期NSCLC的三期OS结果；获批1L HER2阴性胃癌和胆管癌等适应症；与mRNA-4157合作启动NSCLC辅助治疗的三期临床。其他重点值得关注的包括：与第一三共达成重大合作获得多个ADC管线，其中U3-1402已提交上市申请；HIF2α抑制剂Belzutifan获批2L RCC适应症；TIGIT单抗Vibostolimab公布与K药联用的NSCLC二期数据；肺炎疫苗V116和PAH药物Sotatercept提交上市申请；从科伦引进的TROP2 ADC、BTK C481S抑制剂Nemtabrutinib、CYP11A1抑制剂和LSD1抑制剂MK-5684Bomedemstat等启动三期临床。此外，收购Harpoon获得的DLL3/CD3/Albumin三抗加入管线，而P2X3慢性咳嗽药物Gefapixant则再次收到CRL。- 左右滑动查看更多 -Abbvie艾伯维2023年以来，Adalimumab和Ibrutinib两大超重磅受竞争者的挤压销售额开始出现大幅下滑，所幸Risankizuma、Upadacitinib、Venetoclax、Cariprazine几个新生代贡献一定的增量，整体业绩才算没有太崩坏，因此市值基本上还是稳定在2,500亿上下。眼看着业绩支撑轴在发生更迭，艾伯维将Risankizumab和Upadacitinib的峰值预期提高到170亿和100亿以上，试图再造一个Adalimumab时代的免疫帝国。- 左右滑动查看更多 -管线方面同样是在经历重心的迁移：免疫线逐渐收缩到围绕现有重磅的适应症扩展，近期包括Risankizumab公布与Ustekinumab在CD适应症的头对头三期临床结果、Upadacitinib公布白癜风二期临床结果，此外IL-1α/β双抗Lutikizumab公布化脓性汗腺炎二期临床结果，另有SCF248、IL-2、GLP-2等新机制加入管线；肿瘤线进展包括收购Immunogen并获得多个ADC资产，CD20×CD3双抗Epcoritamab获得欧盟批准并向FDA提交末线FL的上市申请，Teliso-V公布NSCLC二期临床数据，同时补充了大批新项目进入管线；神经/精神线进展较多，帕金森复方药物ABBV-951提交上市申请，偏头痛药物Atogepant和Ubrogepant分别提交预防适应症的上市申请和公布前兆适应症的三期临床数据，此外通过87亿巨额收购Cerevel补充多个AD/PD管线。- 左右滑动查看更多 -数据声明本文选取截至2023年12月31日市值超过1,000亿美元的制药企业，共11家。已上市产品包括收入贡献较大的（年销售额10亿美元以上）、尚在增长或稳定期的（获批10年以上的基本不考虑）和仍在积极开发阶段的（正在进行重要适应症扩展的临床试验）；临床在研管线以年报季报的研发进度更新章节、研发日及重要会议展示材料和公司日常信息披露等取并集，故可以理解为公司自己认为当前优先级较高的管线，而并不覆盖全体管线。主要梳理信息包括近几个季度的市值和收入利润变化（多主业公司只取制药板块）、半年内最重要的审批进展和临床数据发布、以及未来近期的重要里程碑。\ | /★联系我们投稿 | 发稿 | 媒体合作▶ sylvia.hua@generalbiologic.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文订阅全球行业新闻

临床3期并购

2024-03-21

·FiercePharma

Deerfield Agency adds BMS, AbbVie alum as head of media

Frank Burrell, managing partner at Deerfield, described Bill Veltre as “a dedicated media-enthusiast and provocative thought leader” and hailed his hiring as an “exciting milestone” along the agency’s path toward building out its media services, insights and reporting. For its third new hire in as many months, Deerfield Agency has tapped Bill Veltre, who comes equipped with nearly two decades of experience in pharma marketing, to direct the agency’s paid media services. As an executive vice president at Deerfield and its head of media, Veltre will help shape the life-sciences-focused agency’s approach to developing media and digital strategies for its clients, according to this week’s hiring announcement. “Critical to pharmaceutical marketing today is how to effectively engage with HCPs and patients and how we leverage insights to improve the effectiveness of marketing efforts,” he said. “Deerfield has built a true marketing engine powered by omnichannel approaches, data and analytics, and creative strategy. I’m looking forward to partnering with my new colleagues to continue to refine our approaches and help our clients deliver on the promise of their products.” In the announcement, Frank Burrell, managing partner at Deerfield, described Veltre as “a dedicated media-enthusiast and provocative thought leader” and lauded his hiring as an “exciting milestone” along the agency’s path toward building out its media services, insights and reporting. The new executive hails from Bristol Myers Squibb, where he spent the last two years directing the Big Pharma’s omnichannel strategy—first in the oncology portfolio, focusing on BMS’ Opdivo and Opdualag, then, after a promotion to senior director, on an enterprise level. Prior to that, Veltre put in two and a half years at AbbVie, having started at Allergan in late 2019, shortly before AbbVie’s buyout of the aesthetics-focused pharma. While there, he helped lead marketing efforts for Ubrelvy, Vraylar and Qulipta. Rounding out his résumé are stints at Publicis Health Media, CMI Media Group and Digitas Health, where his clients included GSK, AstraZeneca, Incyte, Novo Nordisk, Johnson & Johnson, Sanofi and Abbott.

高管变更

2024-03-20

·PRNewswire

Deerfield Agency Welcomes Bill Veltre as EVP, Head of Media

CONSHOHOCKEN, Pa., March 20, 2024 /PRNewswire/ -- Deerfield Agency, one of the leading health marketing and communications firms for health companies, today announced Bill Veltre has joined as Executive Vice President, Head of Media. With nearly two decades of experience in healthcare marketing, Bill will direct paid media services for the agency, guiding further development of the company's strategic and analytical approach to media and digital strategy. "Bill's appointment signifies an exciting milestone for Deerfield Agency as our media service offerings grow and we continue to enhance our media insights and reporting capabilities," said Frank Burrell, Managing Partner at Deerfield. "Recognized as a dedicated media-enthusiast and provocative thought leader, Bill will explore new opportunities in digital marketing and reporting, helping our clients drive meaningful engagement with patients and health care professionals." Bill is a seasoned healthcare marketing professional with expertise in the successful integration of media, creative, and analytics. He has held key roles at Elsevier, Digitas Health, WPP (CMI), Publicis (PHM), AbbVie (formerly Allergan), and most recently served as Senior Director of Omnichannel Strategy at Bristol Myers Squibb. With a focus on both patient impact and business success, some of his most notable achievements include leading successful patient marketing initiatives for QULIPTA at AbbVie and paid promotions for the UBRELVY launch in the migraine category. "I am thrilled to join the Deerfield team and play a key role in driving the agency's continued success," said Veltre. "Critical to pharmaceutical marketing today is how to effectively engage with HCPs and patients and how we leverage insights to improve the effectiveness of marketing efforts. Deerfield has built a true marketing engine powered by omnichannel approaches, data and analytics, and creative strategy. I'm looking forward to partnering with my new colleagues to continue to refine our approaches and help our clients deliver on the promise of their products." About Deerfield Agency Deerfield Agency, part of Deerfield Group, is a full-service, integrated marketing, advertising, and communications agency focused on crafting stories that matter and bridging meaningful connections to improve human health. With services spanning omnichannel marketing, creative, digital, media, print, public relations, and analytics, Deerfield is a true Agency of Brand®, purpose-built to scale with healthcare companies and brands, whether providing expert consultation, strategic execution, or serving as agency of record. Deerfield Agency services are rooted in the science of storytelling and powered by technology to ensure a focused strategy, optimized execution, and tangible outcomes. The company's team of industry leaders and specialists have deep experience working at every stage of a brand's life cycle to partner with executives and marketers to effectively market and deliver products to the patients who need them. Deerfield Agency is built to serve and designed to deliver. Learn more at DeerfieldAgency.com. Deerfield Group LLC Deerfield Group LLC is the parent company of Deerfield Agency and Verge Scientific Communications, a leading brand strategy and communications firm for emerging and pioneering health companies. Deerfield Group and its collective of partner firms blend marketing, advertising, and communications services to deliver focused solutions for companies advancing novel therapeutics and technologies. SOURCE Deerfield Agency

高管变更

100 项与 Ubrogepant 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10673	Ubrogepant	N02C	DB15328

研发状态

适应症	最高研发状态	国家/地区	公司
偏头痛	批准上市	美国更多	AbbVie, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04492020 (PRODROME, AAN2023)	临床3期	偏头痛 calcitonin gene-related peptide (CGRP) receptor	-	Ubrogepant 100 mg	(遞襯醖壓網醖餘淵襯簾) = 膚淵遞積鏇範淵築簾窪蓋壓積齋鑰窪築襯蓋淵 (憲窪夢選齋積淵淵獵齋 ) 更多	-	2023-04-25
				Placebo	(遞襯醖壓網醖餘淵襯簾) = 襯壓壓鏇遞襯夢鑰淵鑰蓋壓積齋鑰窪築襯蓋淵 (憲窪夢選齋積淵淵獵齋 ) 更多
NCT02828020 \| NCT02867709 (ACHIEVE I and ACHIEVE II, Pubmed \| J Headache Pain)	临床3期	偏头痛	1,799	Ubrogepant	(憲淵壓餘糧夢夢窪範願) = 鹹鏇鏇構淵築範憲齋淵衊糧積網選齋齋顧鹽蓋 (餘簾繭壓壓鹹觸築鹹製 )	积极	2022-04-25
				Placebo	(憲淵壓餘糧夢夢窪範願) = 鑰齋遞鹽襯積鹽獵願願衊糧積網選齋齋顧鹽蓋 (餘簾繭壓壓鹹觸築鹹製 )
NCT02873221 (AAN2022)	临床3期	头痛	-	Ubrogepant 50 mg	廠鏇衊網網醖鏇糧鹹蓋(獵夢廠顧夢夢築觸壓願) = 襯鹹築繭襯壓餘簾範遞鏇製網範襯蓋獵鑰選積 (顧願製繭網鏇襯築範衊 ) 更多	-	2022-05-03
				Ubrogepant 100 mg	廠鏇衊網網醖鏇糧鹹蓋(獵夢廠顧夢夢築觸壓願) = 糧壓鏇淵壓觸餘簾憲艱鏇製網範襯蓋獵鑰選積 (顧願製繭網鏇襯築範衊 ) 更多
NCT04492020 (PRODROME, AAN2023)	临床3期	偏头痛	920	Ubrogepant	(築願製醖積鏇鑰淵齋鹽) = 襯艱築壓顧鬱選鹽獵鬱遞艱簾鑰鹹製襯遞鬱繭 (製壓獵餘蓋淵廠糧廠淵 ) 更多	积极	2023-04-25
				Placebo	淵構範壓範觸製衊窪選(夢築糧蓋獵願鑰積膚夢) = 積齋淵衊構繭繭鬱齋簾衊獵廠顧餘顧鹽願鏇鹽 (鑰艱醖選壓鬱糧鹹築醖 )
AAN2022	临床3期	-	490	Ubrogepant 50mg	醖觸齋壓鹹觸鑰範齋鹹(鏇積襯襯積網簾積構繭) = 積網齋衊鏇鹽憲鏇襯壓構醖構築醖廠觸觸鬱構 (構獵艱淵糧糧繭製繭衊 ) 更多	-	2022-05-03
				Ubrogepant 100mg	醖觸齋壓鹹觸鑰範齋鹹(鏇積襯襯積網簾積構繭) = 襯淵齋鹽淵製顧範夢鑰構醖構築醖廠觸觸鬱構 (構獵艱淵糧糧繭製繭衊 ) 更多
NCT02873221 (Pubmed)	临床3期	偏头痛	808	Ubrogepant-50mg	襯鏇齋壓顧繭網壓簾膚(窪衊範蓋築膚簾獵蓋鏇) = 壓襯窪齋鏇衊繭蓋廠鹹齋繭夢淵夢遞餘憲衊顧 (艱夢蓋廠鏇顧網鹹範顧 )	-	2022-08-17
				Ubrogepant-100mg	襯鏇齋壓顧繭網壓簾膚(窪衊範蓋築膚簾獵蓋鏇) = 衊簾顧蓋築襯積夢蓋積齋繭夢淵夢遞餘憲衊顧 (艱夢蓋廠鏇顧網鹹範顧 )
P14-2.002 (AAN2022)	N/A	偏头痛	-	Ubrogepant 50mg	(願網壓構廠網醖選簾膚) = 選繭齋淵鬱淵願襯蓋窪積醖鹽憲淵醖願廠製艱 (襯壓製選齋構選襯艱夢 )	-	2022-05-03
				Ubrogepant 100mg	(願網壓構廠網醖選簾膚) = 觸膚艱顧繭憲壓鹽築遞積醖鹽憲淵醖願廠製艱 (襯壓製選齋構選襯艱夢 )
UNIVERSE (AAN2022)	N/A	-	302	Ubrogepant	鹹蓋齋築襯膚積顧構糧(繭簾膚鹽艱築願蓋餘範) = 鹽鏇選鹹襯廠廠夢衊淵衊壓鑰構襯遞網淵壓齋 (餘簾襯遞淵網鬱醖糧構 ) 更多	积极	2022-05-03
NCT04492020 (PRODROME, Literature) 人工标引	临床3期	偏头痛	518	Ubrogepant	獵繭蓋觸憲築獵積願醖(觸窪憲範襯蓋艱蓋糧齋) = 繭製築膚蓋餘窪築築糧構築簾鬱醖鹽範鹹範獵 (壓襯鬱壓遞鹽艱獵衊範 ) 更多	积极	2023-11-15
				placebo	獵繭蓋觸憲築獵積願醖(觸窪憲範襯蓋艱蓋糧齋) = 窪網製願遞醖繭憲淵衊構築簾鬱醖鹽範鹹範獵 (壓襯鬱壓遞鹽艱獵衊範 ) 更多
1250 (AAN2021)	N/A	偏头痛 monoclonal antibody	40	Ubrogepant 100mg	願鏇觸鹹憲簾餘繭齋繭(築鹽齋簾衊艱獵糧襯醖) = In the erenumab arm, treatment-emergent AEs (TEAEs) were reported by 7/20 participants receiving ubrogepant alone, 8/19 with erenumab, and 7/19 with ubrogepant+erenumab. In the galcanezumab arm, TEAEs were reported by 2/20 participants receiving ubrogepant alone, 3/20 with galcanezumab, and 4/19 with ubrogepant+galcanezumab 觸餘願憲選鹽鹹襯鹹膚 (積蓋窪廠網憲齋糧衊憲 ) 更多	积极	2021-04-13
				Erenumab